Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Background. Intravenous alemtuzumab and fludarabine are effective in combination for the treatment of chronic lymphocytic leukemia (CLL), but require hospital visits for intravenous injection. We performed a pilot study to assess the safety and efficacy of outpatient-based oral fludarabine with subc...
Saved in:
| Main Authors: | William Y. K. Hwang, Claire Dearden, Yvonne S. M. Loh, Yeh C. Linn, Sim L. Tien, Gerrard K. H. Teoh, Gee F. How, Kee K. Heng, Yeow T. Goh, Lai H. Lee |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2009-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2009/547582 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabine
by: E. V. Kataeva, et al.
Published: (2014-07-01) -
Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
by: N Yalman, et al.
Published: (2000-07-01) -
Alemtuzumab in treatment of chronic lymphocytic leukemia
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
First research of use Vero-Fludarabine in chronic lymphocytic leukemia and non-hodgkins lymphoma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01) -
Lower Number of Fludarabine Cycles in Patients with Lymphoid Malignancies
by: Donald Pasquale
Published: (2014-08-01)